Free Trial
NASDAQ:GHRS

GH Research (GHRS) Stock Price, News & Analysis

$11.05
-0.60 (-5.15%)
(As of 04:15 PM ET)
Today's Range
$11.05
$12.04
50-Day Range
$10.98
$14.81
52-Week Range
$5.05
$14.99
Volume
39,270 shs
Average Volume
98,267 shs
Market Capitalization
$574.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.67

GH Research MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
231.8% Upside
$36.67 Price Target
Short Interest
Bearish
4.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.84) to ($1.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.50 out of 5 stars

Medical Sector

732nd out of 896 stocks

Pharmaceutical Preparations Industry

341st out of 425 stocks

GHRS stock logo

About GH Research Stock (NASDAQ:GHRS)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GHRS Stock Price History

GHRS Stock News Headlines

GH Research (NASDAQ:GHRS) Trading Up 4.7%
3 Psychedelic Stocks to Ride to the Moon and Beyond
Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
See More Headlines
Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/03/2024
Today
7/19/2024
Next Earnings (Estimated)
8/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GHRS
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.67
High Stock Price Target
$40.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+231.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-35,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.94 per share

Miscellaneous

Free Float
30,384,000
Market Cap
$574.93 million
Optionable
Optionable
Beta
0.86
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

  • Mr. Florian Schonharting M.Sc. (Econ) (Age 55)
    Co-Founder & Non-Executive Chairman of the Board
  • Dr. Theis Terwey M.D. (Age 48)
    Co-Founder & CEO
  • Mr. Magnus Halle (Age 27)
    Co-Founder & MD of Ireland
  • Ms. Julie Ryan F.C.A. (Age 38)
    Vice President of Finance
  • Mr. Aaron Cameron M.B.A. (Age 39)
    Chief Operating Officer
  • Mr. Naoise Gaffney
    VP & Head of Intellectual Property
  • Dr. Velichka Valcheva M.D. (Age 49)
    Chief Medical Officer

GHRS Stock Analysis - Frequently Asked Questions

How have GHRS shares performed this year?

GH Research's stock was trading at $5.80 at the beginning of 2024. Since then, GHRS shares have increased by 90.5% and is now trading at $11.05.
View the best growth stocks for 2024 here
.

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) posted its quarterly earnings data on Friday, May, 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07.

When did GH Research IPO?

GH Research (GHRS) raised $150 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GHRS) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners